SCHEMBL13625432

SCHEMBL13625432

CC(C)Cc1ccc(-c2cncs2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD38 P28907 2/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
KMT2A Q03164 1/20 0.39
CARM1 Q86X55 3/20 0.38
PRMT1 Q99873 3/20 0.38
DYRK1A Q13627 1/20 0.38
PTPRF P10586 1/20 0.38
PTPN1 P18031 1/20 0.38
PTPRA P18433 1/20 0.38
XDH P47989 1/20 0.37
PTGS1 P23219 3/20 0.36
PTGS2 P35354 3/20 0.36
LMNA P02545 2/20 0.36
CYP2C9 P11712 2/20 0.36
AKR1C3 P42330 2/20 0.36
CXCR1 P25024 2/20 0.36
CXCR2 P25025 2/20 0.36
ALB P02768 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13637132 0.79 CD38 (0.42) CD38POLBMAPTCARM1PRMT1
SCHEMBL16298860 0.77 HRH3 (0.52) CD38CARM1PRMT1DYRK1A
SCHEMBL9261090 0.76 HDAC4 (0.43) CD38MAPTDYRK1A
SCHEMBL12515632 0.76 MKNK1 (0.47) CD38MAPTCARM1PRMT1DYRK1A
SCHEMBL12936656 0.75 CARM1 (0.46) CD38CARM1PRMT1DYRK1APTGS2
SCHEMBL10034581 0.74 SLC6A2 (0.47) CD38CARM1PRMT1DYRK1AHTR2A
SCHEMBL10131071 0.74 MAPT (0.38) MEN1POLBMAPTKMT2APTPRF
SCHEMBL8636154 0.73 MEN1 (0.53) MEN1POLBMAPTKMT2AXDH
SCHEMBL5018819 0.73 LTA4H (0.61) MEN1POLBMAPTKMT2ACYP2C9
SCHEMBL10332122 0.73 PTPRF (0.42) MEN1POLBMAPTKMT2APTPRF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622452-B2 C-9 alkenylidine bridged macrolides ENANTA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-7622452-B2 C-9 alkenylidine bridged macrolides ENANTA PHARMACEUTICALS, INC. (US) 2009-11-24 US disclosed
US-20080119418-A1 C-9 ALKENYLIDINE BRIDGED MACROLIDES ENANTA PHARMACEUTICALS, INC. 2008-05-22 US disclosed
US-20080119418-A1 C-9 ALKENYLIDINE BRIDGED MACROLIDES ENANTA PHARMACEUTICALS, INC. 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119418-A1 C-9 ALKENYLIDINE BRIDGED MACROLIDES CYP2C9, CCR9, DPP9 CD38 287/4885MEN1 3930/4885POLB 3994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.